Pablo J. SantaMaria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pablo J. SantaMaria has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Martha K. Terris
Medical College of Georgia, Department of Urology, 1447 Harper Street, Augusta, GA, 30912, United States of America
3 shared publications - Om V. Sakhalkar
Augusta Univ, Med Coll Georgia, Dept Urol, Augusta, GA USA
2 shared publications - Bradley Morganstern
Children's Hospital of Georgia, 1446 Harper St, Augusta, GA 30912, USA
1 shared publication - Gustavo Capo
The Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication - Jackson McClain
The Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
1 shared publication - Joshua van der Eerden
Medical College of Georgia, 1120 15th St, Augusta, GA 30912, United States of America
1 shared publication
Latest Publications
- Open Access
- 7 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5584
Prevalence and Phenotype of Lower Urinary Tract Symptoms in Fibromyalgia: A Retrospective Observational Study at a Single Tertiary Medical Center
Background: Fibromyalgia syndrome (FMS) is a complex condition with poorly understood pathophysiology, characterized by widespread pain and an increasing recognition of its associations with genitourinary symptoms. The objective of this study was to characterize the prevalence, phenotype, and common comorbidities of lower urinary tract symptoms (LUTS) in women with FMS. Methods: A retrospective observational study was conducted using electronic medical records of 440 women diagnosed with FMS at a single institution between 1 January 2018, and 1 January 2024. Study subjects were evaluated for diagnoses associated with LUTS, including interstitial cystitis (IC), overactive bladder (OAB), and stress urinary incontinence (SUI), alongside comorbidities such as irritable bowel syndrome (IBS), generalized anxiety disorder (GAD), and major depressive disorder (MDD). Multivariate analyses were performed to assess predictors of conditions associated with LUTS. Results: LUTS were identified in 37.0% of FM patients. GAD and IBS were significantly associated with conditions associated with LUTS (OR = 4.62; OR = 8.53, p < 0.001). SUI was present in 17.05% of patients, falling between survey-based and confirmed prevalence rates in the general population. IC was diagnosed in 2.95% of FMS patients. OAB was observed in 6.8% of patients and associated with GAD (OR = 5.98, p < 0.001). Conclusions: This study highlights a substantial burden of diagnoses associated with LUTS in patients with FMS. There is relatively high prevalence of SUI and IC in this dataset. IBS and GAD were commonly found to co-occur with one or more LUTS-associated condition. Future prospective studies are needed to investigate a multimodal approach to the treatment of LUTS in these patients.
- 7 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5584
Open AccessPrevalence and Phenotype of Lower Urinary Tract Symptoms in Fibromyalgia: A Retrospective Observational Study at a Single Tertiary Medical Center
Background: Fibromyalgia syndrome (FMS) is a complex condition with poorly understood pathophysiology, characterized by widespread pain and an increasing recognition of its associations with genitourinary symptoms. The objective of this study was to characterize the prevalence, phenotype, and common comorbidities of lower urinary tract symptoms (LUTS) in women with FMS. Methods: A retrospective observational study was conducted using electronic medical records of 440 women diagnosed with FMS at a single institution between 1 January 2018, and 1 January 2024. Study subjects were evaluated for diagnoses associated with LUTS, including interstitial cystitis (IC), overactive bladder (OAB), and stress urinary incontinence (SUI), alongside comorbidities such as irritable bowel syndrome (IBS), generalized anxiety disorder (GAD), and major depressive disorder (MDD). Multivariate analyses were performed to assess predictors of conditions associated with LUTS. Results: LUTS were identified in 37.0% of FM patients. GAD and IBS were significantly associated with conditions associated with LUTS (OR = 4.62; OR = 8.53, p < 0.001). SUI was present in 17.05% of patients, falling between survey-based and confirmed prevalence rates in the general population. IC was diagnosed in 2.95% of FMS patients. OAB was observed in 6.8% of patients and associated with GAD (OR = 5.98, p < 0.001). Conclusions: This study highlights a substantial burden of diagnoses associated with LUTS in patients with FMS. There is relatively high prevalence of SUI and IC in this dataset. IBS and GAD were commonly found to co-occur with one or more LUTS-associated condition. Future prospective studies are needed to investigate a multimodal approach to the treatment of LUTS in these patients.
- Open Access
- 9 April 2025
- Published by Elsevier in Urology Case Reports
- Vol. 60, 103035
Consequences of a non-supplemented pediatric vegan diet: Nephrolithiasis & nutritional calcipenic rickets
- 9 April 2025
- Published by Elsevier in Urology Case Reports
- Vol. 60, 103035
Open AccessConsequences of a non-supplemented pediatric vegan diet: Nephrolithiasis & nutritional calcipenic rickets
- Open Access
- 3 February 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (2) , rjae064
Transgender patient undergoing Rezum therapy: a case report
Rezūm is a relatively new, minimally invasive approach that utilizes vaporized water to ablate prostatic tissue surrounding the proximal urethra in patients with benign prostatic hyperplasia. However, of the many notable studies involving Rezūm’s effectiveness in men, none have documented use of Rezūm in the transgender community. With a growing population of transgender patients in the USA, prostate treatments will be offered for transgender women on a more regular basis. To the best of our knowledge, we introduce the first case of Rezūm being utilized to treat benign prostatic hyperplasia in a patient self-identifying as a woman.
- 3 February 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (2) , rjae064
Open AccessTransgender patient undergoing Rezum therapy: a case report
Rezūm is a relatively new, minimally invasive approach that utilizes vaporized water to ablate prostatic tissue surrounding the proximal urethra in patients with benign prostatic hyperplasia. However, of the many notable studies involving Rezūm’s effectiveness in men, none have documented use of Rezūm in the transgender community. With a growing population of transgender patients in the USA, prostate treatments will be offered for transgender women on a more regular basis. To the best of our knowledge, we introduce the first case of Rezūm being utilized to treat benign prostatic hyperplasia in a patient self-identifying as a woman.